Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00687-17. Print 2017 Oct.
Linezolid serum trough () and peak () levels were determined prospectively in 90 patients. Adequate exposure was defined as a of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.
前瞻性地测定了 90 例患者的利奈唑胺血清谷值（）和峰值（）水平。充分暴露定义为 2 至 8 毫克/升。治疗是经验性的（73.3%）或靶向性的（26.7%）。记录到利奈唑胺水平的个体间差异很大（0.1 至 25.2μg/ml）。总体而言，65.5%的患者的浓度不在治疗范围内，41.1%的患者的浓度低于治疗范围，24.4%的患者的浓度高于治疗范围。我们没有发现异常水平与不良事件、住院死亡率或总体不良预后之间存在相关性。
